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The concept of 3 is
central to religion,
philosophy, physics,
and chemistry. This
concept now comes
to the field of car-
diovascular disease,
where the troika of
transformation
made up of trans-
formational tech-
nology (TAVR),
transformational
relationships, and
transformational
approaches will
change our world.Irrespective of the field, be it religion (the 3 main Abrahamic religions, Hinduism,or Buddhism), philosophy (Hegel’s dialectic), physics (baryon), chemistry (atomicconstituents), or anatomy (human light perception), the underlying structure of 3’s
has been accorded considerable attention.
This underlying structure of 3’s has great relevance right now to the American College of
Cardiology (ACC) and the Society of Thoracic Surgeons (STS) as 3 occurrences converge,
each of which is transformational. Such alignment brings with it tremendous opportunities.
Transformational technology. The continued drive towards less invasive strategies of
care has led to the development, testing, and, more recently the approval of transcatheter
or transvascular aortic valve replacement (TAVR). This is truly transformational technol-
ogy in that it finally offers an alternative for patients with severe aortic stenosis who are
too high risk for surgical aortic valve replacement. Now evaluated in a single pivotal ran-
domized clinical trial, and the subject of another ongoing randomized clinical trial, this
technology has been used worldwide in more than 45,000 patients in more than 40
countries and is transforming the care of ill, debilitated, and elderly patients who previ-
ously had no option.
Transformational relationships. There has always been a natural tension between inter-
ventional cardiology and cardiovascular surgery. At times this has become manifest in stri-
dent debates and at other times in a polarization of attitudes and approaches that confuse
patients’ families and referring physicians alike. Beginning with the SYNTAX trial, and the
novel concept of heart teams, the chasm is beginning to be bridged. With the advent of
TAVR and the ever-expanding relationship between the STS and the ACC, heart teams are
gaining even further traction. Both the STS and the ACC bring different strengths (and, it
is even possible, different weaknesses) to the table. Working in close collaboration, we are
forging a future for heart teams that will only be enhanced by this partnership.
TAVR has also provided a unique opportunity for the STS and the ACC to work
more closely with industry, as well as the U.S. Food and Drug Administration (FDA)
and the Centers for Medicare and Medicaid Services (CMS). This novel, multi-stake-
holder collaboration of professional societies, industry, and governmental agencies is a
first of its kind. As these relationships grow ever deeper and more robust, they too will
change the landscape and hopefully serve as a new paradigm for future innovative tech-
nologies and therapies.
Transformational approaches. The third part of the troika is the development of trans-
formational approaches. An example of this is the collaboration among the ACC, STS,
FDA, CMS, and industry to develop the STS/ACC TVT RegistryTM. This unique reg-
stry, which was imagined, discussed, and implemented in 3 short months (yet another 3),
erves as the main repository for clinical data related to TAVR. It will allow the cardio-
ascular profession to monitor important safety information, detect infrequent complica-
ions, and build the robust clinical research infrastructure necessary to advance the sci-
nce surrounding the TAVR procedure.
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to post-approval studies and post-market surveillance and
is intended to be the poster child for new device develop-
ment, approval, and reimbursement strategies. By linking
the NCDR and STS databases, it will subsequently be-
come a robust research engine for comparative effective-
ness and cost-effectiveness research. The governance of
this registry includes representatives from the STS, ACC,
FDA, and CMS. A Research and Publications Subcom-
mittee and Stakeholder Advisory Group also allow for
input from industry trial sponsors, consumers, researchers,
and health plans so that the registry benefits from the
wisdom of many constituencies.
The concept of 3 is central to religion, philosophy,
physics, and chemistry. This concept now comes to thefield of cardiovascular disease, where the troika of trans-
formation made up of transformational technology
(TAVR), transformational relationships, and transforma-
tional approaches will change our world. Amazingly it has
all happened in the past 3 months.
From your ACC and STS to you!
For more information on the TVT RegistryTM, go to
ww.ncdr.com/tvt.
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